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Urinary Incontinence (MUI) and Urge Urinary Incontinence
(UUI) in Germany over 12 months. METHODS: PURE is an
ongoing six-month, pan-European, prospective observational
study to determine direct treatment costs for women with UI.
Analysis includes 2175 German patients (mean age 65.1 years)
with SUI (n = 487), MUI (n = 1457) or UUI (n = 231) symptoms.
Participating investigators are ofﬁce based primary care physi-
cians (n = 110), urologists (n = 185), gynaecologists (n = 100)
and other (n = 4). Resource use data for cost estimation was col-
lected retrospectively including medication, conservative treat-
ment, diagnostic and surgical procedures, incontinence products
and visits to health care providers for 12 months preceding base-
line. Unit costs for 2004 from the perspective of statutory health
insurance (SHI) were used. RESULTS: Average total annual costs
for women with UI ranged from 413.0€ for SUI, 438.0€ for UUI
to 585.2€ for MUI. Costs were primarily attributable to pad
costs for SUI (223.5€), MUI (300.3€) and UUI (235.0€). A total
of 52.4% of pad costs were incurred by SHI, with remaining
costs being paid out-of-pocket. Average drug costs were 47.4€
for SUI, 86.1€ for MUI and 107.2€ for UUI. Patients receiving
UI surgery had average surgical costs of 3326.9€. On average,
26.9% of patients with SUI, 44.0% with MUI and 52.8% with
UUI were treated with UI medication, while 10.3% of patients
with SUI, 16.8% with MUI and 17.5% with UUI were ever
treated with surgery. Pad use ranged from 85%, 87.2% to 89.2%
in SUI, MUI and UUI patients, respectively. CONCLUSION:
Patients with MUI were found to incur the highest costs com-
pared to patients with other UI subtypes. Patients with SUI were
treated with UI medication not indicated for use in SUI. Inci-
dence of previous UI surgery was considerable in this treatment
seeking population.
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TREATMENT OF INSTITUTIONALIZED PATIENTS WITH
ALZHEIMER’S DISEASE WITH QUETIAPINE: A COST-
EFFECTIVENESS EVALUATION
Getsios D1, O’Brien J2, Caro JJ2, Pesa J3
1Caro Research Institute, Hammonds Plains, NS, Canada; 2Caro
Research, Concord, MA, USA; 3AstraZeneca LP, Wilmington, DE, USA
OBJECTIVE: Over 75% of individuals with Alzheimer’s disease
(AD) residing in nursing homes have behavioral and psycholog-
ical signs of dementia (BPSD). Quetiapine is an atypical antipsy-
chotic that has demonstrated effectiveness in the treatment of
BPSD. This analysis examines the health economic implications
of treating patients with AD and BPSD with quetiapine at a dose
of 200mg per day. METHODS: A discrete event simulation was
developed to compare treatment of institutionalized AD patients
in the US with quetiapine relative to no pharmacological treat-
ment. The model follows individuals over one year, tracking
changes in BPSD and the resulting inﬂuence on costs. Effective-
ness and treatment persistence estimates are based on a ran-
domized, double-blind trial comparing quetiapine to placebo,
while BPSD related nursing home costs are derived from the
Minnesota Case Mix Research Database and published infor-
mation. Costs in the simulation, which are reported in 2004 US
dollars, include nursing home per diems, physician visits, psy-
chiatric and behavioral services, and treatment with quetiapine.
The primary effectiveness outcome is time without clinically sig-
niﬁcant BPSD. RESULTS: Untreated patients incur costs averag-
ing $49,350 per year, clinically signiﬁcant BPSD apparent 87%
of the time. Treatment with quetiapine costs $1142 per year, but
this is entirely offset in savings from other areas, resulting in net
savings of $44 per year. At the same time, patients spend seven
fewer weeks with clinically signiﬁcant BPSD. In repeated simu-
lations, quetiapine dominated no treatment in almost 60% of
replications. In 94% of replications, quetiapine was either dom-
inant or led to incremental costs per BPSD year avoided of under
$5000. Sensitivity analyses showed that variations in BPSD-
speciﬁc nursing home costs had the strongest impact on out-
comes. CONCLUSIONS: These analyses indicate that quetiap-
ine in patients with AD and BPSD is cost-effective and may even
lead to overall health care system savings.
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OVERCOMING SAMPLE-SELECTION CHALLENGES IN
ECONOMIC COMPARISONS OF DRUG AND NON-DRUG
THERAPY: THE CASE OF OVERACTIVE BLADDER
Ollendorf DA1, Jumadilova Z2,Varadharajan S1, Girase P1
1PharMetrics, Inc, Watertown, MA, USA; 2Pﬁzer, Inc, New York, NY,
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OBJECTIVE: To assess whether comparable populations can be
created to assess the economic impact of different treatment
strategies for overactive bladder (OAB). METHODS: Data 
were obtained from the PharMetrics Patient-Centric Database 
on patients diagnosed with OAB between January, 2001 and
December, 2002. Patients were stratiﬁed into those receiving a
pharmacological therapy for OAB (ie, long-acting tolterodine,
immediate- or extended-release oxybutynin) versus medical 
management alone. Patients were matched 1 :1 by the estimated
propensity score for OAB pharmacotherapy. A logistic regression
model included selected demographic and clinical characteristics.
A ﬁtted probability of receipt of OAB medication was generated
for all patients, and matching was performed based on a differ-
ence of ± 0.01 in this probability. Differences in patient charac-
teristics as well as outcomes and costs during follow-up were
assessed using descriptive statistics (chi-squares for proportions,
Wilcoxon rank-sum tests for continuous variables). RESULTS:
A total of 29,992 matched pairs were identiﬁed. Patients aver-
aged 50 years of age, and 75% were women. After matching,
differences in all patient characteristics were nonsigniﬁcant, with
the exception of physician specialty. Both groups had a pre-index
Charlson Comorbidity Index of 0.70. The incidence of urinary
tract infection was higher in the group receiving medical man-
agement alone (27.4% vs. 20.2%, p < 0.0001). Mean (± SD)
OAB-related costs were also signiﬁcantly higher in the medical
management group ($454 ± $2559 vs. $253 ± $1985, p <
0.0001). Pharmacy costs were higher in the drug-treated group,
but total costs (OAB-related and unrelated) were numerically
similar ($8666 ± $22,757 vs. $8674 ± $20,496), suggesting that
high pharmacological costs of treatment are offset by reduction
in other OAB- and infection-related costs. CONCLUSIONS:
Creation of comparable cohorts is feasible, even when treatment
interventions differ substantially. Furthermore, OAB pharma-
cotherapy appears to be cost-neutral in the management of the
condition, and may impart selected clinical beneﬁts.
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ECONOMIC EVALUATION OF ONDANSETRON VERSUS
DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE
VOMITING IN CHILDREN
Piwko C1, Lasry A1,Alanezi K1, Coyte PC1, Ungar WJ2
1University of Toronto,Toronto, ON, Canada; 2The Hospital for Sick
Children,Toronto, ON, Canada
OBJECTIVE: Postoperative vomiting (POV) is a distressing com-
plication and its incidence ranges from 34%–90% in children
undergoing strabismus surgery when antiemetics are not ad-
ministered prophylactically. This study compares the economic
beneﬁt of ondansetron versus dimenhydrinate as antiemetics
administered prophylactically in children undergoing strabismus
surgery. METHODS: This study, conducted at Toronto’s Hospi-
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tal for Sick Children, reviews 70 charts representing healthy chil-
dren who had strabismus surgery and were given ondansetron
or dimenhydrinate prophylactically. Cost-consequence analysis 
is used to compare costs and outcomes. Cost information was
obtained from the ﬁnance department and the hospital phar-
macy. Cost items include the acquisition cost of the antiemetics,
the cost of administering the agents, the cost length of stay in
the post anesthetic care unit (PACU) and the cost of an episode
of emesis, including laundry expense, materials, nursing time,
housekeeping time and rescue treatment. The outcome measure
used to determine the effectiveness of the antiemetics is the
number of POV-free patients. This represents patients that did
not experience POV that would have otherwise done so without
the prophylactic administration of an antiemetic. RESULTS: In
an adjusted cohort of 100, the number of POV-free patients 
was 45.3 for ondansetron and 38.2 for dimenhydrinate. The
costs per patient were CAD$185.34 for ondansetron and
CAD$232.34 for dimenhydrinate. The length of stay in the
PACU represented over 97% of total costs, and the mean lengths
of stay in the PACU for ondansetron and dimenhydrinate were
signiﬁcantly different, 3.43 and 4.41 hours, respectively. CON-
CLUSION: Ondansetron is more effective in reducing POV and
less expensive than dimenhydrinate. However, the dominance
ondansetron offers over dimenhydrinate is dependent on the
length of stay in the PACU. This study should serve as a pilot
for a larger scale investigation on the correlation between the
length of stay in the PACU and the antiemetic agent used.
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BODY MASS INDEX (BMI) AND TRENDS IN GP
CONSULTATIONS AND PRESCRIBING: A UK NHS
PERSPECTIVE
Boler A1, Lister SP2
1Heron Evidence Development, Letchworth, UK; 2CompuFile Ltd,
Woking, Surrey, UK
OBJECTIVE: To assess trends in UK GP consultations and pre-
scribing according to BMI classiﬁcation. METHODS: The 
DIN-LINK longitudinal patient database comprises 1.5 million
anonymised medical records from GP practices across Great
Britain. This analysis was based on a cohort of 75,738 DIN-
LINK patients, with BMI status recorded, who had seen their GP
in the year ending August 2004. Patients were grouped accord-
ing to three BMI classiﬁcations: normal (BMI < 25), overweight
(25–30) and obese (>30). We examined the mean number of con-
sultations per patient and the lengths of these consultations in
the three groups. The number and type of prescriptions issued
were also measured. RESULTS: The mean number of consulta-
tions per patient increased as patients’ BMI increased from
normal to obese. Patients with a BMI below 25 saw their GP a
mean 6.4 times [SD 36.5] during the year; this was signiﬁcantly
lower than patients who were overweight (7.5 [35.5]). Patients
classiﬁed as obese had the highest mean number of consultations
at 8.7 [35.3]. This trend was repeated when the number of pre-
scriptions issued per consultation was investigated. In the normal
BMI group a mean 0.87 prescriptions were issued per consulta-
tion, increasing to 0.99 for the overweight individuals; this rose
again to 1.17 in the obese group. Over the course of the year,
obese patients were issued with a mean 10.3 prescriptions,
almost twice as many as normal BMI patients (mean 5.6). There
appeared to be only slight increases in the lengths of consulta-
tions as BMI classiﬁcation increased from normal to obese.
CONCLUSION: Our preliminary analysis shows that patients
with a higher BMI are likely to visit their GP more frequently,
and be issued with more prescriptions, than those of normal
weight. The length of a consultation, however, does not appear
to be inﬂuenced greatly by BMI status.
DB6
COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-
BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN
DETEMIR + INSULIN ASPART OR HUMAN INSULIN-BASED
REGIMENS IN THE NETHERLANDS
Valentine WJ1,Wittrup-Jensen K2, Palmer AJ1, Roze S1
1CORE—Center for Outcomes Research, Binningen, Basel,
Switzerland; 2Novo Nordisk A/S, Bagsvaerd, Denmark
OBJECTIVES: In patients with type-1 diabetes, poor glycemic
control is associated with increased risk of complications. A
recent clinical study provided evidence that basal/bolus treat-
ment with insulin detemir+insulin aspart (IDet/IAsp) improved
HbA1c (0.22%-points lower after 18 weeks), reduced risk of
hypoglycemic events (by 21%), and decreased body mass index
(BMI) (-0.3kg .m-2) in comparison to neutral protamine Hage-
dorn insulin+human soluble insulin (NPH/HSI). The aim of this
study was to evaluate the long-term impact of these short-term
clinical beneﬁts in patients with type-1 diabetes in the Dutch
setting. METHODS: We used a validated computer simulation
model (CORE Diabetes Model) to project long-term clinical and
cost outcomes in patients receiving IDet/IAsp or NPH/HSI based
on the clinical study ﬁndings. Standard Markov sub-models were
combined to simulation the incidence and progression of com-
plications (cardiovascular disease, neuropathy, renal and eye
disease). Transition probabilities and HbA1c-dependent adjust-
ments were derived from published sources. Baseline cohort
characteristics and treatment effect data were based on the clin-
ical study. Direct costs were retrieved from published sources and
projected over patient lifetimes from a Dutch National Health
Care perspective. Costs and clinical beneﬁts were discounted 
at 4% per annum. RESULTS: IDet/IAsp treatment was associ-
ated with fewer diabetes-related complications, improved life
expectancy (0.15 life years gained) and quality-adjusted life
expectancy (0.10 QALYs gained) compared to NPH/HSI. Mean
total lifetime costs were 872€ per patient higher with IDet/IAsp,
leading to incremental cost-effectiveness ratios (ICERs) of 5813€
per life year and 8720€ per QALY gained. CONCLUSION:
Short-term clinical beneﬁts in glycemic control, hypoglycemic
event rates and BMI associated with IDet/IAsp basal/bolus
therapy were projected to lead to fewer complications, and
improved life expectancy and quality-adjusted life expectancy
over patient lifetimes compared to NPH/HSI. This resulted in
ICERs for IDet/IAsp versus NPH/HSI in the range considered to
represent excellent value for money.
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THE EFFECT OF OBESITY ADJUSTMENTS ON COST-
EFFECTIVENESS MODELS OF DIABETES PREVENTION
Novak S, Lawson K,Wilson J
University of Texas at Austin, Austin,TX, USA
OBJECTIVES: Obesity adjustments may have a substantial
effect on models of long-term cost-effectiveness of intensive
lifestyle intervention to prevent type -2 diabetes (T2DM). The
objectives of this study were to: 1) design a long-term cost-
effectiveness model to evaluate the use of lifestyle intervention
to prevent progression from impaired glucose tolerance (IGT) to
T2DM; and 2) to analyze the effect of obesity adjustments for
mortality and costs on the model. METHODS: Markov models
were developed based on the DPP results incorporating the states
of normal glucose tolerance (NGT), IGT, T2DM and death.
Transition probabilities were derived from DPP and current lit-
